Biodexa Partners with Syngene for MTX240 GMP Supplies
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 02 2026
0mins
Source: Newsfilter
- MTX240 Production Partnership: Biodexa has partnered with Syngene to manufacture both the active pharmaceutical ingredient and dosage form of MTX240 under GMP standards, showcasing a strong collaboration that is expected to expedite clinical trial timelines.
- Innovative Mechanism Advantage: MTX240 employs molecular glue technology to stabilize a complex of PDE3a and SLFN12 proteins specifically in GIST cells, offering a novel therapeutic approach that may provide new hope for TKI-resistant patients, highlighting its significant clinical implications.
- Clinical Trial Plans: Biodexa plans to file an IND and initiate a Phase 1b/2a clinical study by the end of the year, which will include a dose escalation phase followed by an expansion phase aimed at generating efficacy signals in TKI-resistant GIST patients, indicating substantial market potential.
- Broad Market Outlook: As GIST patients increasingly develop resistance to existing TKIs, the unique mechanism of MTX240 may fill a critical gap in the market, further enhancing Biodexa's competitive position within the biopharmaceutical industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BDRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BDRX
About BDRX
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. The Company’s lead development program, eRapa, is under development for familial adenomatous polyposis and non-muscle invasive bladder cancer; tolimidone, under development as a for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications, including recurrent glioblastoma, diffuse midline glioma, or DMG, and medulloblastoma. Its technologies include Q-Sphera, MidaCore and MidaSolve. The Q-Sphera platform is a polymer microsphere microtechnology used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months. Its MidaSolve platform is an oligosaccharide nanotechnology that is used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biodexa Pharmaceuticals Raises $3.5 Million Through Offerings
- Offering Structure: Biodexa Pharmaceuticals announced a registered offering priced at $2.85 per share, aiming to raise $0.8 million, alongside a $1 million private placement and a $1.7 million warrant inducement, indicating active engagement in capital markets with expected total proceeds of approximately $3.5 million.
- Warrant Arrangement: The company agreed to reduce the exercise price of existing warrants to $2.85 and plans to issue new unregistered Series O warrants for 1.22 million ADS, subject to shareholder approval, aimed at attracting investors and enhancing liquidity.
- Use of Proceeds: The net proceeds from the offerings will fund the company's development programs, working capital, and other general corporate purposes, reflecting the company's commitment to advancing its clinical-stage biopharmaceutical projects.
- Market Performance: BDRX shares have traded between $2.45 and $66.50 over the past year, closing at $2.91, although down 3.09% in after-hours trading to $2.82, indicating a mixed market sentiment but overall confidence in the stock.
See More
Biodexa Pharmaceuticals Annual General Meeting Results
- Voting Results: At Biodexa Pharmaceuticals' Annual General Meeting held on June 30, 2026, ordinary resolutions 1 through 7 passed with majorities of 94%, 73%, 92%, 81%, 81%, 91%, and 94%, indicating strong shareholder support for the company's strategic direction.
- Failed Resolutions Impact: Despite the passage of most ordinary resolutions, the failure of ordinary resolution 8 and special resolution 10 resulted in the failure of resolution 11, which may impact the company's future strategic direction and financing capabilities.
- R&D Pipeline Overview: Biodexa focuses on developing innovative products for unmet medical needs, with key development programs including eRapa for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer, and MTX240 for Gastrointestinal Stromal Tumors, showcasing the company's potential in cancer treatment.
- Company Background: Biodexa Pharmaceuticals is headquartered in Cardiff, UK, and is committed to developing biopharmaceutical products with potential market value, which could drive company growth through the success of its R&D pipeline.
See More
Biodexa Receives Health Canada Approval to Expand FAP Trial
- Trial Expansion: Biodexa has received approval from Health Canada to expand its Serenta registrational Phase 3 trial into Canada, expected to add three to four new clinical centers, thereby enhancing patient recruitment and supporting the company's market expansion in the FAP sector.
- Recruitment Progress: The Serenta trial is currently active in 29 recruiting centers, with 73 patients enrolled out of a target of 168, and the recruitment pace has accelerated significantly with the opening of European centers, addressing the urgent need for new therapeutic options.
- Funding Support: The Phase 3 trial is backed by a $20 million grant from the Cancer Prevention and Research Institute of Texas, underscoring the project's significance in cancer research while providing robust financial support for Biodexa's R&D efforts.
- Market Potential: With no effective treatment options currently available for FAP patients, the positive feedback on Serenta indicates significant market potential, positioning Biodexa's innovative products to fill this gap and enhance the company's competitiveness in the biopharmaceutical industry.
See More
Biodexa Pharmaceuticals Postpones Annual General Meeting
- AGM Postponement: Biodexa Pharmaceuticals' Annual General Meeting originally scheduled for 11:00 AM today was adjourned due to lack of quorum, meaning shareholder voting rights and decision-making processes are temporarily hindered as the meeting cannot be reconvened for 10 clear days.
- Rescheduled Meeting: The rescheduled AGM will take place on June 30, 2026, at 11:00 AM at the company's Cardiff office, ensuring that all proxies submitted for the original meeting remain valid, thus preserving shareholder engagement and participation rights.
- R&D Pipeline Overview: Biodexa focuses on developing innovative products for unmet medical needs, with key programs including eRapa for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer, and MTX240 for Gastrointestinal Stromal Tumors, highlighting the company's potential in the biopharmaceutical sector.
- Future Outlook: While the postponement of the AGM may temporarily affect shareholder confidence, Biodexa's R&D projects like tolimidone, which shows promise in diabetes treatment, could drive future growth, especially against the backdrop of a rapidly expanding diabetes market.
See More
Biodexa Issues Shareholder Letter on Capital Reorganization
- Annual Meeting Notice: Biodexa Pharmaceuticals PLC will hold its Annual General Meeting on June 17, 2026, where shareholders will receive a voting card to discuss several resolutions related to the reorganization of share capital aimed at simplifying the company's share management.
- Share Count Adjustment: As of May 6, 2026, the company had 373,056,808,922 ordinary shares outstanding, and plans to consolidate these into 37,305,681 shares by merging every 10,000 shares into one, thereby reducing complexity and optimizing operations.
- ADS Ratio Change: Following the reorganization, the ordinary share to American Depositary Shares (ADS) ratio will change from 500,000:1 to 50:1, ensuring that the number of ADSs remains unchanged, which aims to protect shareholder rights and simplify the shareholder structure.
- Board's Voting Recommendation: The Biodexa Board unanimously recommends shareholders vote in favor of all proposals, emphasizing that this reorganization will enhance corporate governance efficiency and strengthen market competitiveness.
See More
Biodexa Partners with Syngene, Shares Surge 69%
- Stock Surge: Biodexa Pharmaceuticals Plc (BDRX) shares are climbing approximately 69% in Thursday morning trading, currently priced at $1.05, reflecting strong market enthusiasm for its new partnership.
- Manufacturing Partnership: The company has entered into a collaboration with Syngene International Ltd to manufacture both the MTX240 active pharmaceutical ingredient and dosage form, which is expected to enhance production capacity and expedite product launch.
- Price Volatility Range: Over the past year, BDRX's stock has traded between $0.6010 and $19.300, with the current price performance indicating investor confidence in the company's future, particularly driven by the new partnership.
- Clinical Research Plans: Biodexa plans to file an IND and initiate a Phase 1b/2a study by the end of the year, which not only advances its R&D efforts but may also attract new investment opportunities and market attention.
See More
Biodexa Pharmaceuticals Raises $3.5 Million Through Offerings
- Offering Structure: Biodexa Pharmaceuticals announced a registered offering priced at $2.85 per share, aiming to raise $0.8 million, alongside a $1 million private placement and a $1.7 million warrant inducement, indicating active engagement in capital markets with expected total proceeds of approximately $3.5 million.
- Warrant Arrangement: The company agreed to reduce the exercise price of existing warrants to $2.85 and plans to issue new unregistered Series O warrants for 1.22 million ADS, subject to shareholder approval, aimed at attracting investors and enhancing liquidity.
- Use of Proceeds: The net proceeds from the offerings will fund the company's development programs, working capital, and other general corporate purposes, reflecting the company's commitment to advancing its clinical-stage biopharmaceutical projects.
- Market Performance: BDRX shares have traded between $2.45 and $66.50 over the past year, closing at $2.91, although down 3.09% in after-hours trading to $2.82, indicating a mixed market sentiment but overall confidence in the stock.
See More
Biodexa Pharmaceuticals Annual General Meeting Results
- Voting Results: At Biodexa Pharmaceuticals' Annual General Meeting held on June 30, 2026, ordinary resolutions 1 through 7 passed with majorities of 94%, 73%, 92%, 81%, 81%, 91%, and 94%, indicating strong shareholder support for the company's strategic direction.
- Failed Resolutions Impact: Despite the passage of most ordinary resolutions, the failure of ordinary resolution 8 and special resolution 10 resulted in the failure of resolution 11, which may impact the company's future strategic direction and financing capabilities.
- R&D Pipeline Overview: Biodexa focuses on developing innovative products for unmet medical needs, with key development programs including eRapa for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer, and MTX240 for Gastrointestinal Stromal Tumors, showcasing the company's potential in cancer treatment.
- Company Background: Biodexa Pharmaceuticals is headquartered in Cardiff, UK, and is committed to developing biopharmaceutical products with potential market value, which could drive company growth through the success of its R&D pipeline.
See More
Biodexa Receives Health Canada Approval to Expand FAP Trial
- Trial Expansion: Biodexa has received approval from Health Canada to expand its Serenta registrational Phase 3 trial into Canada, expected to add three to four new clinical centers, thereby enhancing patient recruitment and supporting the company's market expansion in the FAP sector.
- Recruitment Progress: The Serenta trial is currently active in 29 recruiting centers, with 73 patients enrolled out of a target of 168, and the recruitment pace has accelerated significantly with the opening of European centers, addressing the urgent need for new therapeutic options.
- Funding Support: The Phase 3 trial is backed by a $20 million grant from the Cancer Prevention and Research Institute of Texas, underscoring the project's significance in cancer research while providing robust financial support for Biodexa's R&D efforts.
- Market Potential: With no effective treatment options currently available for FAP patients, the positive feedback on Serenta indicates significant market potential, positioning Biodexa's innovative products to fill this gap and enhance the company's competitiveness in the biopharmaceutical industry.
See More
Biodexa Pharmaceuticals Postpones Annual General Meeting
- AGM Postponement: Biodexa Pharmaceuticals' Annual General Meeting originally scheduled for 11:00 AM today was adjourned due to lack of quorum, meaning shareholder voting rights and decision-making processes are temporarily hindered as the meeting cannot be reconvened for 10 clear days.
- Rescheduled Meeting: The rescheduled AGM will take place on June 30, 2026, at 11:00 AM at the company's Cardiff office, ensuring that all proxies submitted for the original meeting remain valid, thus preserving shareholder engagement and participation rights.
- R&D Pipeline Overview: Biodexa focuses on developing innovative products for unmet medical needs, with key programs including eRapa for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer, and MTX240 for Gastrointestinal Stromal Tumors, highlighting the company's potential in the biopharmaceutical sector.
- Future Outlook: While the postponement of the AGM may temporarily affect shareholder confidence, Biodexa's R&D projects like tolimidone, which shows promise in diabetes treatment, could drive future growth, especially against the backdrop of a rapidly expanding diabetes market.
See More
Biodexa Issues Shareholder Letter on Capital Reorganization
- Annual Meeting Notice: Biodexa Pharmaceuticals PLC will hold its Annual General Meeting on June 17, 2026, where shareholders will receive a voting card to discuss several resolutions related to the reorganization of share capital aimed at simplifying the company's share management.
- Share Count Adjustment: As of May 6, 2026, the company had 373,056,808,922 ordinary shares outstanding, and plans to consolidate these into 37,305,681 shares by merging every 10,000 shares into one, thereby reducing complexity and optimizing operations.
- ADS Ratio Change: Following the reorganization, the ordinary share to American Depositary Shares (ADS) ratio will change from 500,000:1 to 50:1, ensuring that the number of ADSs remains unchanged, which aims to protect shareholder rights and simplify the shareholder structure.
- Board's Voting Recommendation: The Biodexa Board unanimously recommends shareholders vote in favor of all proposals, emphasizing that this reorganization will enhance corporate governance efficiency and strengthen market competitiveness.
See More
Biodexa Partners with Syngene, Shares Surge 69%
- Stock Surge: Biodexa Pharmaceuticals Plc (BDRX) shares are climbing approximately 69% in Thursday morning trading, currently priced at $1.05, reflecting strong market enthusiasm for its new partnership.
- Manufacturing Partnership: The company has entered into a collaboration with Syngene International Ltd to manufacture both the MTX240 active pharmaceutical ingredient and dosage form, which is expected to enhance production capacity and expedite product launch.
- Price Volatility Range: Over the past year, BDRX's stock has traded between $0.6010 and $19.300, with the current price performance indicating investor confidence in the company's future, particularly driven by the new partnership.
- Clinical Research Plans: Biodexa plans to file an IND and initiate a Phase 1b/2a study by the end of the year, which not only advances its R&D efforts but may also attract new investment opportunities and market attention.
See More
